Sanofi-manager hopes to match Victoza
The recent approval of Lyxumia creates a new frontline in the battle for market shares between Sanofi and Novo Nordisk. Learn why Sanofi’s Danish manager thinks they will win - or at least tie - and get an analyst’s perspective on the matter.
by Kresten Morten Munksgaard
The battle for control of the diabetes market between Novo Nordisk and Sanofi will not just be fought on the market for long-acting insulin.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”And we want to do it again and again and again”
For abonnenter
